1. Is a Confirmed Case of Moderate COVID-19 infection. <br/ > <br/ >2.The patient must exhibit the following criteria: <br/ > a)SpO2: <94% (range 90-94%) on room air. <br/ > b)Respiratory Rate: â?¥ 24/ minute (range â?¥ 24 - 30), <br/ > <br/ >3.The patient may show any one or more of the below clinical symptoms: <br/ > a)Fever <br/ > b)Cough <br/ > c)Dyspnoea and/or hypoxia <br/ > <br/ >4.Male or non-pregnant female adult requiring hospitalization, with or without comorbidities between the age group of 18-65 years of age at time of screening. <br/ > <br/ >5.Women of childbearing potential must agree to either abstain or use at least one primary form of contraception not including hormonal contraception from the time of screening to the end of study (Day 28 or live hospital discharge, whichever is earlier). <br/ > <br/ >6.Agrees not to participate in another clinical trial for the treatment of COVID-19 until the end of study (Day 28 or live hospital discharge, whichever is earlier). <br/ > <br/ >7.Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. <br/ > <br/ >8.Patients ability in the investigators opinion to comply with the protocol procedures. <br/ >

1. Is a Confirmed Case of Moderate COVID-19 infection. <br/ > <br/ >2.The patient must exhibit the following criteria: <br/ > a)SpO2: <94% (range 90-94%) on room air. <br/ > b)Respiratory Rate: â?¥ 24/ minute (range â?¥ 24 - 30), <br/ > <br/ >3.The patient may show any one or more of the below clinical symptoms: <br/ > a)Fever <br/ > b)Cough <br/ > c)Dyspnoea and/or hypoxia <br/ > <br/ >4.Male or non-pregnant female adult requiring hospitalization, with or without comorbidities between the age group of 18-65 years of age at time of screening. <br/ > <br/ >5.Women of childbearing potential must agree to either abstain or use at least one primary form of contraception not including hormonal contraception from the time of screening to the end of study (Day 28 or live hospital discharge, whichever is earlier). <br/ > <br/ >6.Agrees not to participate in another clinical trial for the treatment of COVID-19 until the end of study (Day 28 or live hospital discharge, whichever is earlier). <br/ > <br/ >7.Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. <br/ > <br/ >8.Patients ability in the investigators opinion to comply with the protocol procedures. <br/ >

1. Is a Confirmed Case of Moderate COVID-19 infection. <br/ > <br/ >2.The patient must exhibit the following criteria: <br/ > a)SpO2: <94% (range 90-94%) on room air. <br/ > b)Respiratory Rate: â?¥ 24/ minute (range â?¥ 24 - 30), <br/ > <br/ >3.The patient may show any one or more of the below clinical symptoms: <br/ > a)Fever <br/ > b)Cough <br/ > c)Dyspnoea and/or hypoxia <br/ > <br/ >4.Male or non-pregnant female adult requiring hospitalization, with or without comorbidities between the age group of 18-65 years of age at time of screening. <br/ > <br/ >5.Women of childbearing potential must agree to either abstain or use at least one primary form of contraception not including hormonal contraception from the time of screening to the end of study (Day 28 or live hospital discharge, whichever is earlier). <br/ > <br/ >6.Agrees not to participate in another clinical trial for the treatment of COVID-19 until the end of study (Day 28 or live hospital discharge, whichever is earlier). <br/ > <br/ >7.Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. <br/ > <br/ >8.Patients ability in the investigators opinion to comply with the protocol procedures. <br/ >

1. Is a Confirmed Case of Moderate COVID-19 infection. <br/ > <br/ >2.The patient must exhibit the following criteria: <br/ > a)SpO2: <94% (range 90-94%) on room air. <br/ > b)Respiratory Rate: â?¥ 24/ minute (range â?¥ 24 - 30), <br/ > <br/ >3.The patient may show any one or more of the below clinical symptoms: <br/ > a)Fever <br/ > b)Cough <br/ > c)Dyspnoea and/or hypoxia <br/ > <br/ >4.Male or non-pregnant female adult requiring hospitalization, with or without comorbidities between the age group of 18-65 years of age at time of screening. <br/ > <br/ >5.Women of childbearing potential must agree to either abstain or use at least one primary form of contraception not including hormonal contraception from the time of screening to the end of study (Day 28 or live hospital discharge, whichever is earlier). <br/ > <br/ >6.Agrees not to participate in another clinical trial for the treatment of COVID-19 until the end of study (Day 28 or live hospital discharge, whichever is earlier). <br/ > <br/ >7.Subject (or legally authorized representative) provides written informed consent prior to initiation of any study procedures. <br/ > <br/ >8.Patients ability in the investigators opinion to comply with the protocol procedures. <br/ >